Condition
Neuroendocrine Neoplasms (Tumours)
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Not Yet Recruiting2
Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT07404176Phase 2RecruitingPrimary
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
NCT07279532Phase 2Not Yet RecruitingPrimary
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
NCT07077564Phase 2Not Yet RecruitingPrimary
The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy
NCT04324502RecruitingPrimary
Mobile Application to Collect PRO Data in NET Patients
Showing all 4 trials